BEIJING, China / CAIRO, Egypt, January 22, 2026 — Recently, a delegation led by Kai Du, Executive Vice President and Chief Commercial Officer (EVP & CCO) of Gan & Lee Pharmaceuticals. (hereinafter referred to as "Gan & Lee", Stock Code: 603087.SH), paid an in-depth multi-day visit to Egypt. During the visit, the delegation held high-level meetings with Egypt's Deputy Prime Minister and Minister of Health and Population, as well as the Chairman of the Egyptian Drug Authority (EDA). The two sides reached broad consensus on accelerating the localized production of insulin, advancing in-depth technology transfer, and optimizing regional supply chain layout, which has laid a solid foundation for deepening China-Egypt strategic cooperation in the biopharmaceutical sector.

Focusing on Diabetes care: Jointly Advancing Local Insulin Capacity Upgrade

At the first stop of the visit, Kai Du and the delegation, along with the CEO of the local partner, attended a meeting with Dr. Khaled Abdel Ghaffar, Egypt's Deputy Prime Minister and Minister of Health and Population. The three parties conducted in-depth discussions on the construction of Egypt's national healthcare system and diabetes prevention strategies. Dr. Ghaffar clearly pointed out that expanding local insulin production capacity and reducing import dependence are core priorities of the national pharmaceutical strategy. In response, Kai Du stated: "As a leading enterprise in China's biopharmaceutical field, Gan & Lee will leverage its core advantages in insulin R&D, production, and technology transfer. Through deep capacity cooperation and technical empowerment, we will help Egypt build an independent and controllable insulin supply system, providing local patients with high-quality and cost-effective treatment options."

Deepening Technology Transfer Partnerships to Accelerate the Localization of Long-Acting Insulin

During the visit, the delegation also held in-depth exchanges with Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA). The two sides focused on topics such as the localized production of long-acting insulin in Egypt, expanding the scale of local manufacturing, strengthening biopharmaceutical investment, prioritizing patient medication, and transferring advanced pharmaceutical technologies to Egypt. Dr. Ghamrawy pointed out that the EDA is committed to strengthening the construction of the local pharmaceutical production system by providing organizational and technical support. Kai Du expressed his appreciation for this and reaffirmed the company's long-term commitment to deeply rooting in the Egyptian market. Kai Du noted that the company will actively promote the implementation of cutting-edge medical innovation achievements in Egypt, relying on technology transfer and localized production to effectively meet the needs of Egyptian patients for high-quality biopharmaceuticals.

This series of visits further clarified Gan & Lee's long-term development vision in Egypt and surrounding markets. Through multi-level and in-depth connection with Egyptian pharmaceutical regulatory authorities, the two sides established a clearer and more efficient communication and collaboration mechanism, laying a solid foundation for the subsequent implementation of localization projects, acceleration of technology transfer, and deepening of capacity cooperation. Gan & Lee will continue to promote cooperation with all parties in Egypt, taking insulin cooperation as a starting point and gradually expanding to all-round collaboration in the biopharmaceutical field, contributing the wisdom and strength of Chinese enterprises to improving Egypt's public health level.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.